About

About Pyramid Labs SFF CDMO Aseptic Fill/Finish Services. Vial and Syringe Filling Lyophilization Analytical Services In-house Bioburden & Sterility Clinical & Commercial Manufacturing Stability Services Clinical & Commercial Labeling Breakloose/Glide Force testing. PPQ High Recovery Vials HRV US based manufacturing sites Drug Product CMC 510k Biologics mAb oligonucleotides peptides small molecules siRna nanoparticles Parenteral filling About Pyramid Labs SFF CDMO Aseptic Fill/Finish Services. Vial and Syringe Filling Lyophilization Analytical Services In-house Bioburden & Sterility Clinical & Commercial Manufacturing Stability Services Clinical & Commercial Labeling Breakloose/Glide Force testing. PPQ High Recovery Vials HRV US based manufacturing sites Drug Product CMC 510k Biologics mAb oligonucleotides peptides small molecules siRna nanoparticles Parenteral filling Pyramid Pharma Services is a U.S.-based clinical-to-commercial fill-finish CDMO with over 26 years of GMP drug product manufacturing experience and more than 35 years in business. We provide aseptic manufacturing and sterile manufacturing solutions for complex injectable drug products, supporting both emerging biotech and established pharmaceutical companies. Our expertise includes oligonucleotides, peptides, biologics, and advanced therapeutics, with integrated capabilities that span formulation development, aseptic fill-finish, lyophilization, prefilled syringe and cartridge filling, device assembly, labeling, packaging, and analytical services. By offering end-to-end drug product manufacturing within a single organization, we reduce complexity, accelerate timelines, and ensure consistent execution from clinical development through commercial supply. Pyramid’s California-based facilities support flexible manufacturing across a range of batch sizes and delivery formats, including vials, prefilled syringes, and cartridges. Ongoing investment in advanced, high-speed fill-finish infrastructure strengthens our ability to deliver scalable, reliable solutions for increasingly complex injectable therapies. Our track record includes over 100 successful IND-enabling programs, multiple commercial products, and a strong history of FDA inspections—demonstrating a consistent focus on quality, compliance, and execution. As a fill-finish CDMO, we partner closely with our clients’ CMC, technical, and regulatory teams to support efficient development and commercialization. We work with companies developing injectable therapies that require a reliable, experienced partner for sterile fill-finish and aseptic drug product manufacturing. If you are advancing a program and evaluating a CDMO for fill-finish or drug product manufacturing, we welcome the opportunity to connect at BIO 2026. Schedule time with our team to discuss your program.